|
On (b)(6) 2018, the patient was treated for an unknown issue.The physician implanted a gore® excluder® aaa endoprosthesis featuring c3® delivery system and gore® excluder® aaa endoprosthesis.The patient tolerated the procedure.On (b)(6) 2023, a type ib endoleak was detected.The physician plans to do a reintervention.Revision was done on move medical case (b)(4).The endoleak was ballooned, and patient tolerated the procedure.
|
|
H6: code c19 - the review of the manufacturing paperwork verified that this lot met all pre-release specifications.H6: code d12 ¿ according to the gore® excluder® aaa endoprosthesis instructions for use, adverse events that may occur and/or require intervention include, but are not limited to, endoleaks.An evaluation of returned images was performed: imaging evaluation: summary: the imaging evaluation performed by a clinical imaging specialist showed the following: one time point is available for evaluation: post-implantation cta dated (b)(6) 2023.Maximum diameter in the left common iliac artery is 45mm.There is lack of distal, contralateral leg (plc271200), device apposition.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|